Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Men such as Tony Webber have limited, and expensive, treatment options for advanced prostate cancer. A new program aims to improve outcomes and dares to mention the word ‘cure’ for some.

Immunotherapies use the power of your immune system to fight your cancer. Vaccines are one form of immunotherapy. Sipuleucel-T is a vaccine used for advanced, metastatic prostate cancer if: It no ...

SAN ANTONIO — A small pilot study delivered a big message about the use of testosterone in men with advanced or metastatic prostate cancer, according to a "Best Abstract" presented at the Sexual ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...